Sana Biotechnology (NASDAQ:SANA) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Sana Biotechnology (NASDAQ:SANA) issued its earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04), Zacks reports.

Sana Biotechnology Trading Up 5.4 %

SANA stock traded up $0.25 on Friday, hitting $4.91. The company’s stock had a trading volume of 2,261,241 shares, compared to its average volume of 1,825,041. The firm has a 50 day moving average of $5.90 and a two-hundred day moving average of $7.53. Sana Biotechnology has a 1 year low of $2.74 and a 1 year high of $12.00. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -3.21 and a beta of 1.45.

Analysts Set New Price Targets

Several research analysts have recently issued reports on SANA shares. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 target price for the company. Citigroup upped their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a report on Friday. Finally, HC Wainwright lowered their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.25.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.